The purpose of this study was to determine the possible use of sPD-1 as an immune marker in patients with metastatic melanoma who were enrolled in a randomized phase II trial testing autologous dendritic cell vaccines (DCV) and autologous tumor cell vaccines (TCV) [11, 12]. This evidence concerns the gene HOXD13 and neoplasm.